Skip Navigation


JAC Advance Access originally published online on October 16, 2009
Journal of Antimicrobial Chemotherapy 2009 64(6):1326-1328; doi:10.1093/jac/dkp374
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
64/6/1326    most recent
dkp374v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Nagano, N.
Right arrow Articles by Arakawa, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagano, N.
Right arrow Articles by Arakawa, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Research letters

Molecular characterization of group B streptococci with reduced penicillin susceptibility recurrently isolated from a sacral decubitus ulcer

Noriyuki Nagano1,2, Kouji Kimura1, Yukiko Nagano1, Hiroaki Yakumaru3 and Yoshichika Arakawa1,*

1 Department of Bacterial Pathogenesis and Infection Control, National Institute of Infectious Diseases, 4-7-1 Musashi-murayama, Tokyo 208-0011, Japan 2 Medical Microbiology Laboratory, Funabashi Municipal Medical Center, 1-21-1 Kanasugi, Funabashi, Chiba 273-8588, Japan 3 Department of Plastic Surgery, Funabashi Municipal Medical Center, 1-21-1 Kanasugi, Funabashi, Chiba 273-8588, Japan

* Corresponding author. Tel: +81-42-561-0771; Fax: +81-42-561-7173; E-mail: yarakawa@nih.go.jp

Keywords: Streptococcus agalactiae , β-lactams , infection , PBP 2X alterations , MLST

The first 10% of the full text of this article appears below.

Sir,

Penicillin is the first-line antibiotic for group B streptococci (GBS) in disease therapy as well as in intrapartum chemoprophylaxis because resistance to this agent has so far not been reported among GBS clinical isolates. However, we have recently reported GBS isolates with reduced penicillin susceptibility (PRGBS), where altered penicillin-binding protein (PBP) 2X demonstrates a major contribution to the reduction of β-lactam susceptibility.1 We have also shown a diversity of mutations in PBP genes among PRGBS, while those genes of the penicillin-susceptible strains . . . [Full Text of this Article]


   Funding
 

   Transparency declarations
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?